We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends Bayer’s Xofigo for Prostate Cancer
NICE Recommends Bayer’s Xofigo for Prostate Cancer
In their second reversal in a week, British healthcare cost monitors are now recommending Bayer’s prostate cancer drug Xofigo for men with hormone-relapsed prostate cancer and symptoms of bone metastases for whom docetaxel chemotherapy has failed.